Difference between revisions of "Team:BGU Israel/Collaborations"
Line 7: | Line 7: | ||
This year we have collaborated with <a href="https://2015.igem.org/Team:Stockholm#">Team Stockholm</a> in human cells expression of an Affibody which presents itself on the plasma membrane. This Affibody could then, for example, bind a toxin or a fluorescent molecule, which will kill or color the cells expressing it. | This year we have collaborated with <a href="https://2015.igem.org/Team:Stockholm#">Team Stockholm</a> in human cells expression of an Affibody which presents itself on the plasma membrane. This Affibody could then, for example, bind a toxin or a fluorescent molecule, which will kill or color the cells expressing it. | ||
Although the collaboration was such that had expressed the Affibody in human cells, without the use of our design, when using our system, specifically our third-plasmid design, the Affibody could be expressed solely in cancerous cells, and introduction of the desired molecule would have an effect only in diseased tissue. | Although the collaboration was such that had expressed the Affibody in human cells, without the use of our design, when using our system, specifically our third-plasmid design, the Affibody could be expressed solely in cancerous cells, and introduction of the desired molecule would have an effect only in diseased tissue. | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
</p> | </p> | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
Revision as of 14:00, 17 July 2015
Collaborations
This year we have collaborated with Team Stockholm in human cells expression of an Affibody which presents itself on the plasma membrane. This Affibody could then, for example, bind a toxin or a fluorescent molecule, which will kill or color the cells expressing it. Although the collaboration was such that had expressed the Affibody in human cells, without the use of our design, when using our system, specifically our third-plasmid design, the Affibody could be expressed solely in cancerous cells, and introduction of the desired molecule would have an effect only in diseased tissue.